Page last updated: 2024-08-03 21:03:30

gkt137831

Description

setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative [MeSH]

Cross-References

ID Source	ID
PubMed CID	58496428
CHEMBL ID	4303187
SCHEMBL ID	1302603
MeSH ID	M0579465

Synonyms (40)

Synonym
SCHEMBL1302603
setanaxib
unii-45ii35329v
2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1h-pyrazolo(4,3-c)pyridine-3,6(2h,5h)-dione
1218942-37-0
45ii35329v ,
gkt-831
gkt 137831
gkt-137831
gkt137831
S7171
setanaxib [inn]
1h-pyrazolo(4,3-c)pyridine-3,6(2h,5h)-dione, 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-
HY-12298
CS-3290
AKOS022176138
2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6(2h,5h)-dione
AC-33132
DTXSID30153432
J-690070
mfcd27923122
EX-A577
AS-74753
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h,2h,3h,5h,6h-pyrazolo[4,3-c]pyridine-3,6-dione
NCGC00378460-08
NCGC00378460-09
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methylpyrazolo[4,3-c]pyridine-3,6(2h,5h)-dione
gkt831
gtpl9932
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione
FT-0700121
BCP14159
1h-pyrazolo[4,3-c]pyridine-3,6(2h,5h)-dione, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-
SB19230
CCG-268595
CHEMBL4303187
Q27258840
2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1,2-dihydro-3h-pyrazolo[4,3-c]pyridine-3,6(5h)-dione
NCGC00378460-05
EN300-20043919

Protein Targets (7)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	18.5569	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	15.0916	AID1645841
G	Vesicular stomatitis virus	Potency	5.3547	AID1645842
Interferon beta	Homo sapiens (human)	Potency	15.2564	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	5.3547	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	5.3547	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	5.3547	AID1645842

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1 ISSN: 2045-2322	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 ISSN: 1464-3391	Highly predictive and interpretable models for PAMPA permeability.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14 ISSN: 1464-3391	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.

Research

Studies (59)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	39 (66.10)	24.3611
2020's	20 (33.90)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (6.67%)	5.53%
Reviews	5 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	51 (85.00%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2010's
b 844-39	1	diarylmethane		2017	2017	7.0	low	1
pk 11195	3	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	2017	2020	5.3	low	3
jtv519	3			2017	2020	5.3	high	3
alprazolam	3	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic	2017	2020	5.3	low	3
dan 2163	3	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic	2017	2020	5.3	low	3
amlexanox	3	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug	2017	2020	5.3	low	3
astemizole	3	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist	2017	2020	5.3	low	3
benzbromarone	3	1-benzofurans; aromatic ketone	uricosuric drug	2017	2020	5.3	low	3
bisindolylmaleimide i	3			2017	2020	5.3	low	3
bufexamac	3	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2017	2020	5.3	low	3
cadralazine	3	organic molecular entity		2017	2020	5.3	low	3
carvedilol	2	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent	2019	2020	4.5	low	2
cetirizine	2	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic	2019	2020	4.5	low	2
chlorcyclizine	3	diarylmethane		2017	2020	5.3	low	3
ci 994	3	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	2017	2020	5.3	low	3
cyclosporine	2			2017	2020	5.5	high	2
fenbendazole	3	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug	2017	2020	5.3	low	3
berotek	1	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent	2017	2017	7.0	low	1
go 6976	3	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor	2017	2020	5.3	low	3
haloperidol	3	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2017	2020	5.3	low	3
homochlorocyclizine	3	diarylmethane		2017	2020	5.3	low	3
hydroxyzine	3	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist	2017	2020	5.3	low	3
ifenprodil	3	piperidines		2017	2020	5.3	low	3
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone	3	naphthalenes		2017	2020	5.3	medium	3
ketamine	3	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic	2017	2020	5.3	low	3
ketoprofen	3	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	2017	2020	5.3	low	3
mebendazole	3	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator	2017	2020	5.3	low	3
mephenesin	3	aromatic ether; glycerol ether		2017	2020	5.3	low	3
niclosamide	3	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	2017	2020	5.3	low	3
oxibendazole	3	benzimidazoles; carbamate ester		2017	2020	5.3	low	3
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine	3			2017	2020	5.3	low	3
perphenazine	3	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug	2017	2020	5.3	low	3
pimobendan	3	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	2017	2020	5.3	low	3
ag 1879	3	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector	2017	2020	5.3	low	3
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	2	indoles		2017	2020	5.5	medium	2
ro 31-8220	3	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor	2017	2020	5.3	low	3
ropinirole	3	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist	2017	2020	5.3	low	3
vorinostat	3	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2017	2020	5.3	low	3
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine	2	stilbenoid		2017	2020	5.5	high	2
trifluperidol	1	aromatic ketone		2017	2017	7.0	low	1
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	3	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	2017	2020	5.3	low	3
zotepine	3	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug	2017	2020	5.3	low	3
colchicine	3	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen	2017	2020	5.3	low	3
benziodarone	3	aromatic ketone		2017	2020	5.3	low	3
cyclizine	1	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic	2019	2019	5.0	low	1
trehalose	3	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2017	2020	5.3	low	3
triclocarban	3	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic	2017	2020	5.3	low	3
4-tert-octylphenol	3	alkylbenzene		2017	2020	5.3	low	3
ethamivan	3	methoxybenzenes; phenols		2017	2020	5.3	low	3
methysergide	3	ergoline alkaloid		2017	2020	5.3	low	3
emetine	3	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor	2017	2020	5.3	low	3
podophyllotoxin	3	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2017	2020	5.3	low	3
etonitazene	3			2017	2020	5.3	low	3
clothiapine	3	dibenzothiazepine		2017	2020	5.3	low	3
benperidol	3	aromatic ketone		2017	2020	5.3	low	3
7-hydroxychlorpromazine	3	phenothiazines		2017	2020	5.3	medium	3
camptothecin	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	2017	2020	5.3	low	3
thenalidine	3	dialkylarylamine; tertiary amino compound		2017	2020	5.3	medium	3
bromocriptine	3	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist	2017	2020	5.3	low	3
dexchlorpheniramine	3	chlorphenamine		2017	2020	5.3	low	3
dv 1006	3			2017	2020	5.3	medium	3
climbazole	3	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes		2017	2020	5.3	low	3
triadimenol	3	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite	2017	2020	5.3	medium	3
amonafide	3	isoquinolines		2017	2020	5.3	low	3
flupirtine	3	aminopyridine		2017	2020	5.3	low	3
chaetochromin	3			2017	2020	5.3	medium	3
enoximone	3	aromatic ketone		2017	2020	5.3	low	3
aripiprazole	3	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist	2017	2020	5.3	low	3
aloxistatin	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor	2019	2019	5.0	low	1
indocate	3			2017	2020	5.3	medium	3
N(4)-acetylsulfathiazole	3	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite	2017	2020	5.3	high	3
cyclizine hydrochloride	2			2017	2020	5.5	medium	2
2,3-trimethylene-4-quinazolone	3	quinazolines		2017	2020	5.3	medium	3
1,3-dimethyluric acid	3	oxopurine	metabolite	2017	2020	5.3	low	3
danofloxacin	3	quinolines		2017	2020	5.3	low	3
nitrefazole	3	imidazoles		2017	2020	5.3	medium	3
methotrimeprazine	3	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist	2017	2020	5.3	low	3
honokiol	3	biphenyls		2017	2020	5.3	low	3
9-methoxyellipticine	3			2017	2020	5.3	low	3
3-aminophenoxazone	3	phenoxazine		2017	2020	5.3	low	3
3-deazaneplanocin	3			2017	2020	5.3	low	3
tryptanthrine	3	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound		2017	2020	5.3	low	3
2-chlorodiazepam	3			2017	2020	5.3	medium	3
Polycartine B	3	phenazines		2017	2020	5.3	high	3
aminoquinuride dihydrochloride	3			2017	2020	5.3	high	3
thioproperazine mesylate	3	phenothiazines		2017	2020	5.3	medium	3
n(6)-(delta(2)-isopentenyl)adenine	3	6-isopentenylaminopurine	cytokinin	2017	2020	5.3	low	3
4-methyl-N-(phenylmethyl)benzenesulfonamide	3	sulfonamide		2017	2020	5.3	medium	3
zpck	2			2019	2020	4.5	low	2
sr141716	3	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist	2017	2020	5.3	low	3
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide	2	aromatic ketone		2017	2020	5.5	high	2
fingolimod	3	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist	2017	2020	5.3	low	3
tesmilifene	3	diarylmethane		2017	2020	5.3	low	3
sr 27897	3	indolyl carboxylic acid		2017	2020	5.3	low	3
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine	3	leucine derivative		2017	2020	5.3	low	3
norketamine	3	organochlorine compound		2017	2020	5.3	low	3
indatraline	2	indanes		2019	2020	4.5	low	2
methotrexate	3	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent	2017	2020	5.3	low	3
salvinorin a	1	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen	2019	2019	5.0	low	1
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide	3			2017	2020	5.3	low	3
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide	3	phenylindole		2017	2020	5.3	low	3
l 741626	3	piperidines		2017	2020	5.3	low	3
dx 8951	3	pyranoindolizinoquinoline		2017	2020	5.3	low	3
tipifarnib	3	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	2017	2020	5.3	low	3
cyc 202	3	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2017	2020	5.3	low	3
avasimibe	3	monoterpenoid		2017	2020	5.3	low	3
l 163191	3			2017	2020	5.3	low	3
dizocilpine	3	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist	2017	2020	5.3	low	3
s-benzylcysteine	3	S-aryl-L-cysteine zwitterion		2017	2020	5.3	high	3
chelidonine	3	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid		2017	2020	5.3	low	3
lapatinib	3	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
roxindole	3	indoles	alpha-adrenergic antagonist; serotonergic drug	2017	2020	5.3	low	3
conidendrin	3			2017	2020	5.3	high	3
Porfiromycine	3	mitomycin		2017	2020	5.3	high	3
nsc 95397	3	1,4-naphthoquinones		2017	2020	5.3	low	3
4-methyl-2-quinazolinamine	3			2017	2020	5.3	high	3
2-glycineamide-5-chlorophenyl-2-pyrryl ketone	3			2017	2020	5.3	high	3
niguldipine hydrochloride	2			2019	2020	4.5	medium	2
2,5-bis(5-hydroxymethyl-2-thienyl)furan	3	thiophenes		2017	2020	5.3	low	3
ritonavir	3	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	2017	2020	5.3	low	3
bardoxolone methyl	1	cyclohexenones		2019	2019	5.0	low	1
Destruxin B	3	cyclodepsipeptide		2017	2020	5.3	high	3
tosylphenylalanyl chloromethyl ketone	3	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor	2017	2020	5.3	low	3
trichostatin a	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector	2019	2019	5.0	low	1
sitafloxacin	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic		2019	2019	5.0	low	1
2'-c-methylcytidine	3			2017	2020	5.3	low	3
jp-1302	3			2017	2020	5.3	medium	3
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one	3	benzodiazepine		2017	2020	5.3	high	3
tenatoprazole	3	imidazopyridine		2017	2020	5.3	low	3
s 1033	3	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
5-[(2-fluoroanilino)methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	3
benidipine hydrochloride	2			2017	2020	5.5	low	2
benidipine	1			2019	2019	5.0	low	1
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	3	quinazolines		2017	2020	5.3	high	3
chlorprothixene	3	chlorprothixene		2017	2020	5.3	medium	3
jrf 12	3			2017	2020	5.3	low	3
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester	3	methoxybenzenes; substituted aniline		2017	2020	5.3	high	3
3-hydroxypyridine, sodium salt	3			2017	2020	5.3	high	3
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide	3	naphthalenecarboxamide		2017	2020	5.3	medium	3
5-[(2-bromoanilino)methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	3
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide	3			2017	2020	5.3	medium	3
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline	3	aromatic amine		2017	2020	5.3	high	3
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide	3	piperidinecarboxamide		2017	2020	5.3	high	3
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	3
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide	3	acetamides; anilide		2017	2020	5.3	high	3
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	3	aromatic amide; thiophenes		2017	2020	5.3	high	3
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone	3	dimethoxybenzene		2017	2020	5.3	high	3
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide	3	aromatic amide		2017	2020	5.3	high	3
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	3	aromatic ether		2017	2020	5.3	high	3
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione	3	maleimides		2017	2020	5.3	high	3
Src Inhibitor-1	3	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2017	2020	5.3	high	3
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one	3	dimethoxybenzene		2017	2020	5.3	high	3
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide	3	quinolines		2017	2020	5.3	high	3
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine	3	pyrroles		2017	2020	5.3	high	3
bi-78d3	3	aryl sulfide		2017	2020	5.3	medium	3
kartogenin	3			2017	2020	5.3	low	3
toremifene	1	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator	2019	2019	5.0	low	1
vx-745	3	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	3
dasatinib	3	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
zd 6474	3	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	2	indoles		2019	2020	4.5	high	2
nih-12848	3			2017	2020	5.3	high	3
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide	3	quinazolines		2017	2020	5.3	high	3
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone	3	benzimidazoles		2017	2020	5.3	high	3
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile	3	imidazopyridine		2017	2020	5.3	high	3
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	3	aromatic ketone		2017	2020	5.3	high	3
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester	3	oxopurine		2017	2020	5.3	high	3
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester	3	organonitrogen compound; organosulfur compound		2017	2020	5.3	high	3
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide	3	quinolines		2017	2020	5.3	high	3
LSM-1924	3	organic heterotricyclic compound; organooxygen compound		2017	2020	5.3	high	3
ferrostatin-1	3	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger	2017	2020	5.3	low	3
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine	3	C-nitro compound		2017	2020	5.3	high	3
rabeprazole(1-)	2	organic nitrogen anion		2019	2020	4.5	high	2
ncgc00099374	3			2017	2020	5.3	high	3
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide	3	benzamides		2017	2020	5.3	high	3
luteolin	3	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist	2017	2020	5.3	low	3
cyclosporine	1			2019	2019	5.0	low	1
kaempferol	3	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite	2017	2020	5.3	low	3
genistein	3	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	2017	2020	5.3	low	3
mycophenolate mofetil	3	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug	2017	2020	5.3	medium	3
bruceantin	3	triterpenoid		2017	2020	5.3	low	3
chrysin	3	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite	2017	2020	5.3	low	3
daidzein	3	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite	2017	2020	5.3	low	3
neticonazole	3	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	2017	2020	5.3	medium	3
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine	3	endocannabinoid; N-acylethanolamine 22:6		2017	2020	5.3	medium	3
n-oleoylethanolamine	3	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist	2017	2020	5.3	low	3
alpha-zearalenol	3	macrolide		2017	2020	5.3	high	3
su 9516	3			2017	2020	5.3	low	3
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	3	triazolopyrimidines		2017	2020	5.3	high	3
sb 277011	3			2017	2020	5.3	low	3
sb 223412	3			2017	2020	5.3	low	3
sr 59230a	3	tetralins		2017	2020	5.3	high	3
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide	3	pyrimidines		2017	2020	5.3	medium	3
kn 62	3	piperazines		2017	2020	5.3	low	3
MeJA	3	Jasmonate derivatives		2017	2020	5.3	high	3
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-	3			2017	2020	5.3	high	3
pd 161570	3			2017	2020	5.3	medium	3
su 11248	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	2017	2017	7.0	low	1
palbociclib	3	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2017	2020	5.3	low	3
jnj-7706621	3	sulfonamide		2017	2020	5.3	low	3
virginiamycin factor s1	3	cyclodepsipeptide; macrolide antibiotic	antibacterial drug; bacterial metabolite	2017	2020	5.3	high	3
fenoterol	2	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent	2019	2020	4.5	low	2
xib 4035	3			2017	2020	5.3	high	3
gw-5074	1			2019	2019	5.0	low	1
belotecan	3	pyranoindolizinoquinoline		2017	2020	5.3	low	3
norgestimate	3	ketoxime; steroid ester; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive	2017	2020	5.3	high	3
b 43	3	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector	2017	2020	5.3	medium	3
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine	3			2017	2020	5.3	medium	3
methiazole	3	benzimidazoles; carbamate ester		2017	2020	5.3	high	3
sb 218795	3	quinolines		2017	2020	5.3	medium	3
bvt.948	3			2017	2020	5.3	high	3
fk 866	1	benzamides; N-acylpiperidine		2019	2019	5.0	low	1
a 38503	3			2017	2020	5.3	medium	3
parthenolide	2	sesquiterpene lactone	drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2017	2019	6.0	medium	2
krn 633	3			2017	2020	5.3	medium	3
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid	3	organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	high	3
gw 501516	3	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist	2017	2020	5.3	low	3
dolastatin 10	3	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent	2017	2020	5.3	low	3
spc-839	3			2017	2020	5.3	low	3
midostaurin	3	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2017	2020	5.3	low	3
valnemulin	2			2019	2020	4.5	medium	2
nu 7026	3	organic heterotricyclic compound; organooxygen compound		2017	2020	5.3	low	3
osi 930	3	aromatic amide		2017	2020	5.3	medium	3
ticagrelor	3	aryl sulfide; hydroxyether; organofluorine compound; secondary amino compound; triazolopyrimidines	P2Y12 receptor antagonist; platelet aggregation inhibitor	2017	2020	5.3	low	3
l 692585	3	peptide		2017	2020	5.3	high	3
pi103	3	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2017	2020	5.3	low	3
nnc 26-9100	3	aminopyridine		2017	2020	5.3	medium	3
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine	3			2017	2020	5.3	high	3
tivozanib	3	aromatic ether		2017	2020	5.3	low	3
hki 272	1	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2019	2019	5.0	low	1
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide	3			2017	2020	5.3	medium	3
tae226	3	morpholines		2017	2020	5.3	low	3
gw0742	3	monocarboxylic acid		2017	2020	5.3	low	3
u 18666a	3	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor	2017	2020	5.3	low	3
sb 525334	3	quinoxaline derivative		2017	2020	5.3	low	3
bx795	3	ureas		2017	2020	5.3	low	3
azd 6244	3	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	3
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea	3			2017	2020	5.3	medium	3
bay 61-3606	3	pyrimidines		2017	2020	5.3	medium	3
sd-208	3			2017	2020	5.3	low	3
crenolanib	3	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	3
cj 033466	3			2017	2020	5.3	high	3
cc 401	3	pyrazoles; ring assembly		2017	2020	5.3	medium	3
PB28	3	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2017	2020	5.3	low	3
arterolane	3			2017	2020	5.3	low	3
cariprazine	3			2017	2020	5.3	low	3
krp-203	3			2017	2020	5.3	high	3
regorafenib	3	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
at 7867	3	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2017	2020	5.3	high	3
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester	3	pyrroloquinoline		2017	2020	5.3	high	3
ptc 124	3	oxadiazole; ring assembly		2017	2020	5.3	low	3
degrasyn	2			2019	2020	4.5	low	2
bi 2536	3			2017	2020	5.3	low	3
azd 1152	3	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug	2017	2020	5.3	medium	3
carfilzomib	3	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2017	2020	5.3	low	3
idelalisib	3	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2017	2020	5.3	low	3
motesanib	3	pyridinecarboxamide		2017	2020	5.3	medium	3
pf-562,271	3	indoles		2017	2020	5.3	medium	3
gliocladin c	3			2017	2020	5.3	high	3
sb 706504	3			2017	2020	5.3	high	3
ku-0060648	3	dibenzothiophenes		2017	2020	5.3	medium	3
bgt226	3	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2017	2020	5.3	medium	3
n-desmethyldanofloxacin	3			2017	2020	5.3	high	3
rabeprazole sodium	1	organic sodium salt		2017	2017	7.0	low	1
azd 1152-hqpa	2	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor	2019	2020	4.5	low	2
CDN1163	3	aromatic ether; quinolines; secondary carboxamide	SERCA activator	2017	2020	5.3	medium	3
gsk 269962a	3			2017	2020	5.3	medium	3
pha 848125	3			2017	2020	5.3	medium	3
nvp-bhg712	3	benzamides		2017	2020	5.3	medium	3
pf 04217903	3	quinolines		2017	2020	5.3	medium	3
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one	3	aromatic ketone		2017	2020	5.3	high	3
ph 797804	3	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	3
srt1720	3			2017	2020	5.3	low	3
purfalcamine	3			2017	2020	5.3	high	3
bms 754807	3	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	3
ponatinib	3	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
quizartinib	3	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor	2017	2020	5.3	low	3
PP121	3	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor	2017	2020	5.3	medium	3
navitoclax	3	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2017	2020	5.3	low	3
gsk 650394	3	phenylpyridine		2017	2020	5.3	medium	3
dcc-2036	3	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor	2017	2020	5.3	medium	3
cabozantinib	3	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	3
TAK-580	3	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor	2017	2020	5.3	medium	3
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one	3	chromones		2017	2020	5.3	high	3
pf 3758309	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	low	3
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	2	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor	2019	2020	4.5	low	2
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	3
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	3
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	3
baricitinib	3	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	2017	2020	5.3	low	3
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	3	quinazolines		2017	2020	5.3	high	3
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	medium	3
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide	3	hydroxyquinoline		2017	2020	5.3	high	3
p505-15	3			2017	2020	5.3	high	3
mrt67307	3	aromatic amine		2017	2020	5.3	medium	3
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide	3	piperazines		2017	2020	5.3	high	3
ribociclib	3			2017	2020	5.3	low	3
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone	3	aromatic ketone; thienopyrimidine		2017	2020	5.3	high	3
pha 793887	3	piperidinecarboxamide		2017	2020	5.3	high	3
gsk 2334470	1	indazoles		2019	2019	5.0	low	1
ml228 probe	3	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator	2017	2020	5.3	high	3
pf-03882845	3			2017	2020	5.3	high	3
jq1 compound	3	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2017	2020	5.3	low	3
pf-04620110	3			2017	2020	5.3	medium	3
gsk525762a	3	benzodiazepine		2017	2020	5.3	low	3
birinapant	1	dipeptide		2019	2019	5.0	low	1
torin 1	3	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor	2017	2020	5.3	medium	3
abt-199	3	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2017	2020	5.3	low	3
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea	3	ureas		2017	2020	5.3	medium	3
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide	3	(trifluoromethyl)benzenes		2017	2020	5.3	high	3
ncgc00242364	3	quinazolines		2017	2020	5.3	high	3
gsk1210151a	3	imidazoquinoline		2017	2020	5.3	low	3
hs-173	3			2017	2020	5.3	high	3
sr1664	3	indolecarboxamide		2017	2020	5.3	high	3
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide	3			2017	2020	5.3	high	3
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide	2	benzamides; N-acylpiperidine		2017	2020	5.5	high	2
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide	2	aminoquinoline		2017	2020	5.5	high	2
cudc-907	3			2017	2020	5.3	low	3
methacycline	1			2019	2019	5.0	low	1
methacycline monohydrochloride	2			2017	2020	5.5	low	2
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid	3	quinolines		2017	2020	5.3	high	3
agi-5198	3			2017	2020	5.3	low	3
cep-32496	3			2017	2020	5.3	medium	3
epz004777	3	N-glycosyl compound		2017	2020	5.3	low	3
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid	3	organonitrogen heterocyclic compound		2017	2020	5.3	medium	3
entecavir	3	benzamides; N-acylpiperidine		2017	2020	5.3	medium	3
vx-509	3			2017	2020	5.3	high	3
vx-970	3	sulfonamide		2017	2020	5.3	low	3
gs-9973	3			2017	2020	5.3	high	3
amg 925	3			2017	2020	5.3	high	3
gne-618	3			2017	2020	5.3	high	3
g007-lk	3			2017	2020	5.3	medium	3
volitinib	3			2017	2020	5.3	high	3
ML355	3	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor	2017	2020	5.3	high	3
acp-196	3	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	3
gsk343	3	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor	2017	2020	5.3	low	3
agi-6780	3			2017	2020	5.3	medium	3
khs101	3			2017	2020	5.3	medium	3
cb-839	3			2017	2020	5.3	low	3
gsk-j4	3	organonitrogen heterocyclic compound		2017	2020	5.3	low	3
pf-06424439	3			2017	2020	5.3	high	3
etp-46464	3			2017	2020	5.3	high	3
onc201	3			2017	2020	5.3	low	3
kai407	3			2017	2020	5.3	high	3
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	3			2017	2020	5.3	high	3
enasidenib	3	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	2017	2020	5.3	low	3
oicr-9429	3			2017	2020	5.3	medium	3
lly-507	3			2017	2020	5.3	medium	3
at 9283	3			2017	2020	5.3	medium	3
hypoxanthine	3	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite	2017	2020	5.3	low	3
clozapine	3	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic	2017	2020	5.3	low	3
1-hydroxyphenazine	3	phenazines		2017	2020	5.3	low	3
ro 24-7429	3	benzodiazepine		2017	2020	5.3	medium	3
nintedanib	3			2017	2020	5.3	low	3
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	3	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor	2017	2020	5.3	high	3
ver 52296	3	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor	2017	2020	5.3	low	3
rvx 208	3			2017	2020	5.3	low	3
bmn 673	3			2017	2020	5.3	low	3

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	2010's	post-2020
gamma-aminobutyric acid	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule	2020	2020	4.0	low	0	1	0
palmitic acid	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite	2018	2018	6.0	low	0	1	0
acetovanillone	1	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite	2017	2017	7.0	low	0	1	0
spironolactone	1	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2019	2019	5.0	low	0	1	0
aldosterone	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite	2019	2019	5.0	low	0	1	0
pyrroles	1	pyrrole; secondary amine		2017	2017	7.0	low	0	1	0
pyrazolanthrone	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2018	2018	6.0	low	0	1	0
benzoxazoles	1	1,3-benzoxazoles; mancude organic heterobicyclic parent		2016	2016	8.0	low	0	1	0
alpha-aminopyridine	1			2019	2019	5.0	low	0	1	0
malondialdehyde	1	dialdehyde	biomarker	2020	2020	4.0	low	0	1	0
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2016	2016	8.0	low	0	1	0
d-alpha tocopherol	1	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite	2020	2020	4.0	low	0	1	0
tocopherols	1			2019	2019	5.0	low	0	1	0
ursodeoxycholic acid	2	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite	2023	2023	1.0	low	2	0	2
calcium oxalate	1	organic calcium salt		2019	2019	5.0	low	0	1	0
triazoles	1	1,2,3-triazole		2016	2016	8.0	low	0	1	0
rosiglitazone	1	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug	2012	2012	12.0	low	0	1	0
phorbol-12-myristate	1			2019	2019	5.0	low	0	1	0
angiotensin ii	3	amino acid zwitterion; angiotensin II	human metabolite	2012	2019	8.3	low	0	3	0
t0901317	1			2020	2020	4.0	low	0	1	0
dactinomycin	1	actinomycin	mutagen	2012	2012	12.0	low	0	1	0
nadp	1			2015	2015	9.0	low	0	1	0
1,1-diphenyl-2-picrylhydrazyl	1			2019	2019	5.0	low	0	1	0
ferrostatin-1	1	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger	2020	2020	4.0	low	0	1	0
dinoprost	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite	2017	2017	7.0	low	0	1	0
8-epi-prostaglandin f2alpha	1	F2-isoprostane	biomarker; bronchoconstrictor agent; vasoconstrictor agent	2017	2017	7.0	low	0	1	0
beta-escin	1			2019	2019	5.0	low	0	1	0
erastin	1	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor	2020	2020	4.0	low	0	1	0
nad	1	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite	2017	2017	7.0	low	0	1	0
interleukin-8	1			2018	2018	6.0	low	0	1	0
transforming growth factor beta	2			2012	2017	9.5	low	0	2	0
allopurinol	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger	2017	2017	7.0	low	0	1	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	2010's	post-2020
Ache	0	1	2020	2020	4.0	low	0	1	0
ACL Injuries	0	1	2019	2019	5.0	low	0	1	0
Acute Brain Injuries	0	1	2017	2017	7.0	low	0	1	0
Acute Kidney Failure	0	1	2019	2019	5.0	low	0	1	0
Acute Kidney Injury	0	1	2019	2019	5.0	low	0	1	0
Acute Lung Injury	0	1	2018	2018	6.0	low	0	1	0
Adenocarcinoma	0	1	2018	2018	6.0	low	0	1	0
Adenocarcinoma, Basal Cell	0	1	2018	2018	6.0	low	0	1	0
Age-Related Macular Degeneration	0	1	2021	2021	3.0	low	0	0	1
Aging	0	1	2016	2016	8.0	low	0	1	0
Albuminuria	0	3	2014	2020	6.0	low	2	3	0
Alloxan Diabetes	0	5	2014	2021	7.2	low	0	4	1
Alveolitis, Fibrosing	0	1	2023	2023	1.0	low	0	0	1
Angiitis	0	1	2020	2020	4.0	low	0	1	0
Angiogenesis, Pathologic	0	1	2019	2019	5.0	low	0	1	0
Anoxemia	0	1	2015	2015	9.0	low	0	1	0
Asymmetric Diabetic Proximal Motor Neuropathy	0	1	2020	2020	4.0	low	0	1	0
Atherogenesis	0	1	2014	2014	10.0	low	0	1	0
Atheroma	0	1	2014	2014	10.0	low	0	1	0
Atherosclerosis	0	1	2014	2014	10.0	low	0	1	0
Autoimmune Chronic Hepatitis	0	1	2012	2012	12.0	low	0	1	0
Autoimmune Diabetes	0	4	2015	2020	5.2	low	2	4	0
Benign Neoplasms	0	1	2020	2020	4.0	low	0	1	0
Biliary Cirrhosis	0	2	2023	2023	1.0	low	2	0	2
Birth Weight	0	1	2018	2018	6.0	low	0	1	0
Blood Pressure, High	0	2	2019	2020	4.5	low	0	2	0
Brain Injuries	0	1	2017	2017	7.0	low	0	1	0
Cancer of Digestive System	0	1	2018	2018	6.0	low	0	1	0
Cancer of Esophagus	0	2	2018	2020	5.0	low	0	2	0
Cancer of Head	0	1	2018	2018	6.0	low	0	1	0
Cancer of Lung	0	2	2016	2018	7.0	low	0	2	0
Cancer of Mouth	0	1	2018	2018	6.0	low	0	1	0
Cancer of Oropharnyx	0	1	2018	2018	6.0	low	0	1	0
Cancer of Prostate	0	1	2018	2018	6.0	low	0	1	0
Cancer of Skin	0	1	2017	2017	7.0	low	0	1	0
Cancer, Radiation-Induced	0	1	2017	2017	7.0	low	0	1	0
Carbon Tetrachloride Poisoning	0	1	2015	2015	9.0	low	0	1	0
Carcinogenesis	0	1	2017	2017	7.0	low	0	1	0
Carcinoma, Epidermoid	0	1	2018	2018	6.0	low	0	1	0
Carcinoma, Non-Small Cell Lung	0	2	2016	2018	7.0	low	0	2	0
Carcinoma, Non-Small-Cell Lung	0	2	2016	2018	7.0	low	0	2	0
Carcinoma, Squamous Cell	1	1	2018	2018	6.0	low	0	1	0
Cardiac Hypertrophy	0	1	2020	2020	4.0	low	0	1	0
Cardiac Remodeling, Ventricular	0	1	2012	2012	12.0	low	0	1	0
Cardiomegaly	0	1	2020	2020	4.0	low	0	1	0
Cirrhosis	0	3	2014	2020	7.0	low	0	3	0
Cirrhosis, Liver	0	4	2012	2015	10.5	low	0	4	0
Colorectal Cancer	0	1	2018	2018	6.0	low	0	1	0
Colorectal Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Congenital Zika Syndrome	0	1	2020	2020	4.0	low	0	1	0
Cruveilhier-Baumgarten Syndrome	0	1	2019	2019	5.0	low	0	1	0
Delayed Effects, Prenatal Exposure	0	1	2018	2018	6.0	low	0	1	0
Dermatoses	0	1	2014	2014	10.0	low	0	1	0
Diabetes Mellitus, Adult-Onset	0	2	2017	2020	5.5	low	0	2	0
Diabetes Mellitus, Type 1	0	4	2015	2020	5.2	low	2	4	0
Diabetes Mellitus, Type 2	0	2	2017	2020	5.5	low	0	2	0
Diabetic Angiopathies	0	1	2014	2014	10.0	low	0	1	0
Diabetic Glomerulosclerosis	0	4	2014	2020	7.5	low	1	4	0
Diabetic Nephropathies	0	4	2014	2020	7.5	low	1	4	0
Diabetic Neuropathies	0	1	2020	2020	4.0	low	0	1	0
Digestive System Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Disease Exacerbation	0	1	2018	2018	6.0	low	0	1	0
Disease Models, Animal	0	11	2014	2020	6.7	low	0	11	0
Erectile Dysfunction	0	1	2021	2021	3.0	low	0	0	1
Esophageal Neoplasms	0	2	2018	2020	5.0	low	0	2	0
Esophageal Squamous Cell Carcinoma	0	1	2020	2020	4.0	low	0	1	0
Fatigue	0	1	2023	2023	1.0	low	1	0	1
Fatty Liver	0	1	2015	2015	9.0	low	0	1	0
Fibrosis	0	3	2014	2020	7.0	low	0	3	0
Group A Strep Infection	0	1	2016	2016	8.0	low	0	1	0
Head and Neck Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Hemorrhage, Subarachnoid	0	1	2017	2017	7.0	low	0	1	0
Hepatitis	0	1	2015	2015	9.0	low	0	1	0
Hepatitis, Autoimmune	0	1	2012	2012	12.0	low	0	1	0
Hypertension	0	2	2019	2020	4.5	low	0	2	0
Hypertension, Portal	0	1	2019	2019	5.0	low	0	1	0
Hypertension, Pulmonary	0	1	2012	2012	12.0	low	0	1	0
Hypoxia	0	1	2015	2015	9.0	low	0	1	0
Idiopathic Parkinson Disease	0	1	2020	2020	4.0	low	0	1	0
Impotence	0	1	2021	2021	3.0	low	0	0	1
Inflammation	0	4	2014	2020	6.5	low	0	4	0
Injury, Ischemia-Reperfusion	0	1	2018	2018	6.0	low	0	1	0
Innate Inflammatory Response	0	4	2014	2020	6.5	low	0	4	0
Insulin Resistance	0	1	2015	2015	9.0	low	0	1	0
Insulin Sensitivity	0	1	2015	2015	9.0	low	0	1	0
Ischemia	0	2	2014	2015	9.5	low	0	2	0
Kidney Calculi	0	1	2019	2019	5.0	low	0	1	0
Kidney Diseases	0	1	2018	2018	6.0	low	0	1	0
Kidney Stones	0	1	2019	2019	5.0	low	0	1	0
Lassitude	0	1	2023	2023	1.0	low	1	0	1
Liver Cirrhosis	0	4	2012	2015	10.5	low	0	4	0
Liver Cirrhosis, Biliary	1	2	2023	2023	1.0	low	2	0	2
Liver Steatosis	0	1	2015	2015	9.0	low	0	1	0
Lung Injury, Acute	0	1	2018	2018	6.0	low	0	1	0
Lung Neoplasms	0	2	2016	2018	7.0	low	0	2	0
Macular Degeneration	0	1	2021	2021	3.0	low	0	0	1
Malnourishment	0	1	2018	2018	6.0	low	0	1	0
Malnutrition	0	1	2018	2018	6.0	low	0	1	0
Mouth Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Neoplasms	0	1	2020	2020	4.0	low	0	1	0
Neuroretinitis	0	1	2015	2015	9.0	low	0	1	0
Obesity	0	1	2015	2015	9.0	low	0	1	0
Oropharyngeal Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Osteoarthritis of Knee	0	1	2019	2019	5.0	low	0	1	0
Osteoarthritis, Knee	0	1	2019	2019	5.0	low	0	1	0
Pain	0	1	2020	2020	4.0	low	0	1	0
Parkinson Disease	0	1	2020	2020	4.0	low	0	1	0
Pregnancy	0	1	2018	2018	6.0	low	0	1	0
Prostatic Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Pulmonary Fibrosis	0	1	2023	2023	1.0	low	0	0	1
Pulmonary Hypertension	0	1	2012	2012	12.0	low	0	1	0
Reperfusion Injury	0	1	2018	2018	6.0	low	0	1	0
Retinitis	0	1	2015	2015	9.0	low	0	1	0
Retinopathy of Prematurity	0	1	2014	2014	10.0	low	0	1	0
Retrolental Fibroplasia	0	1	2014	2014	10.0	low	0	1	0
Rhabdomyosarcoma	0	1	2020	2020	4.0	low	0	1	0
Skin Diseases	0	1	2014	2014	10.0	low	0	1	0
Skin Neoplasms	0	1	2017	2017	7.0	low	0	1	0
Streptococcal Infections	0	1	2016	2016	8.0	low	0	1	0
Subarachnoid Hemorrhage	0	1	2017	2017	7.0	low	0	1	0
Vascular Injuries	0	1	2014	2014	10.0	low	0	1	0
Vasculitis	0	1	2020	2020	4.0	low	0	1	0
Zika Virus Infection	0	1	2020	2020	4.0	low	0	1	0

Safety/Toxicity (1)

Article	Year
Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. Trials, , Jun-03, Volume: 21, Issue:1	2020

Bioavailability (3)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Kidney dysfunction in the low-birth weight murine adult: implications of oxidative stress. American journal of physiology. Renal physiology, , 09-01, Volume: 315, Issue:3	2018
Highly predictive and interpretable models for PAMPA permeability. Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3	2017

gkt137831

Description

Cross-References

Synonyms (40)

Protein Targets (7)

Potency Measurements

Bioassays (9)

Research

Studies (59)

Study Types

Related Drugs (388)

Drugs Involved in Assays Together (357)

Drugs Researched Together (32)

Related Conditions (123)

Safety/Toxicity (1)

Bioavailability (3)